We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pfizer has announced that it has enrolled the first UK participant in a global Phase III study aiming to evaluate its investigational gene therapy candidate in boys with Duchenne muscular dystrophy (DMD).